Drugs like Ozempic and Mounjaro are generating tremendous excitement for weight loss, with new Cochrane reviews confirming they can produce clinically meaningful results. Tirzepatide led to about 16% weight loss over 12 to 18 months, semaglutide produced around 11% reduction, and liraglutide resulted in 4 to 5% weight loss. These are substantial numbers that outperformed placebo consistently. However, here's what concerns me: most studies were funded and designed by the pharmaceutical companies manufacturing these drugs, raising questions about potential conflicts of interest. We have limited data on long-term safety beyond two years, uncertain evidence about cardiovascular outcomes in lower-risk individuals, and concerning patterns of muscle loss and weight regain after stopping treatment. The reviews also found higher rates of gastrointestinal side effects, leading some participants to discontinue treatment. This study highlights these issues and invites caution as we continue to investigate these drugs. In other words, people are trading weight loss with side effects. We need to be very carefully using those GLP1 peptides.

Depression is more than just feeling blue; it's a pervasive mental health condition that affects millions worldwide. According to the Global Burden of Disease Study, depressive disorders saw a staggering 61% increase between 2009 and 2019, making them the most prevalent and burdensome mental health conditions globally. In the United States alone, recent estimates suggest that 18.5% of adults experience depression. This widespread prevalence underscores the urgent need for effective, accessible treatments. Conventional treatments for depression typically involve a combination of psychotherapy and antidepressant medications. Yet, antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) , have a wide range of serious side effects, including elevating the risk of suicidal depression, as well as harm towards self and other. Also, conventional SSRIs are predicated on the monoamine hypothesis, which has been heavily criticized for being myopic. Given the host of side effects associated with these medications, ranging from mild to severe, and problems with efficacy, their use should be more carefully regulated and patients informed of their true risks. Dr. Carol S. Johnston, lead researcher of the vinegar study, notes, "With this lack of consistency regarding the effectiveness and applicability of medical treatment options for depression, research is warranted to further investigate potential treatment methods." In this context, a team of researchers from Arizona State University conducted a randomized controlled trial to explore an unconventional approach: daily vinegar ingestion. The study, published in the journal Nutrients, examined the effects of vinegar consumption on depression symptoms in overweight adults over a four-week period. Study Methodology: The researchers recruited 28 non-smoking men and women aged 18-45 with a body mass index (BMI) between 25-40 kg/m². Participants were randomly assigned to one of two groups: 1. VIN group: Consumed 30 mL (2 tablespoons) of red wine vinegar diluted in water, twice daily with meals. 2. CON group: Took one commercial vinegar pill daily with breakfast.